Abpro Holdings (ABP) Price & Analysis

Compare

113 Followers

ABP Stock Chart & Stats

$3.89

-$0.18(-12.24%)

At close: Jan 08 4:00 PM EST

$3.89

-$0.18(-12.24%)

Day’s Range― - ―

52-Week Range$3.78 - $42.90

Previous Close$1.32

Volume347.98K

Average Volume (3M)4.50M

Market Cap

$10.58M

Enterprise Value$17.37M

Total Cash (Recent Filing)$343.00K

Total Debt (Recent Filing)$147.00K

Price to Earnings (P/E)―

Beta1.40

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding2,716,278

10 Day Avg. Volume2,638,066

30 Day Avg. Volume4,496,030

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)-1.09

Price to Sales (P/S)91.93

P/FCF Ratio-1.86

Enterprise Value/Market Cap1.64

Enterprise Value/Revenue94.92

Enterprise Value/Gross Profit413.56

Enterprise Value/Ebitda-1.43

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strategic Partnership With CelltrionA collaboration with Celltrion that incurs no clinical costs and splits profits equally reduces funding burden and creates a partner-aligned route to commercialization.

Bears Say

Analyst Sentiment And Limited DisclosureA downgrade to Hold tied to strategic uncertainty and financing overhang, along with limited news flow, signals reduced analyst confidence and could weigh on investor sentiment.

Cash Runway And Liquidity RiskAbpro's reported cash balance of $2.1 million combined with a cash burn rate above $2 million per quarter points to imminent funding needs and the potential for dilutive capital raises.

Pipeline Strategic UncertaintyUnclear strategic direction for the bispecific antibody portfolio, including ABP-102 and ABP-201, creates investor uncertainty about development priorities and the programs' future value.

Abpro Holdings News

Abpro Holdings announces ABP-102 featured in presentation

Abpro Holdings (ABP) announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, was featured in a...

5h ago

ABP

Abpro, Celltrion announces U.S. FDA cleared IND application for ABP-102

Abpro announced, together with its co-development partner Celltrion, that the U.S. Food and Drug Administration, FDA, has cleared...

9d ago

ABP

FDA Clears Abpro’s Lead HER2 Cancer Drug for Phase 1

The latest update is out from Abpro Holdings ( ($ABP) ). On January 6, 2026, Abpro Holdings and...

9d ago

ABP

Abpro Holdings Submits IND Application for Cancer Drug

An announcement from Abpro Holdings ( ($ABP) ) is now available. On December 15, 2025, Abpro Holdings, Inc....

1M ago

ABP

Abpro Holdings submits IND application for Phase 1 trial of ABP102/CT-P72

Abpro Holdings (ABP) announced the submission of an investigational new drug application to the U.S. Food and Drug...

1M ago

ABP

Abpro Holdings Granted Nasdaq Compliance Extension

Abpro Holdings ( ($ABP) ) has issued an announcement. On December 9, 2025, Abpro Holdings announced it received...

1M ago

ABP

Abpro Holdings granted listing extension to pursue compliance, objectives

Abpro announced that it has received formal notification from the Nasdaq Hearings Panel granting the Company an extension...

1M ago

ABP

Abpro Holdings files to sell 9.78M shares of common stock for holders

07:43 EST Abpro Holdings (ABP) files to sell 9.78M shares of common stock for holders Published first on...

2M ago

ABP

Abpro Holdings, Celltrion to present preclinical data for CT-P72/ABP-102

Abpro Corporation and Celltrion announced that they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody...

2M ago

ABP

Abpro Holdings Presents Promising Preclinical Data at SITC 2025

The latest announcement is out from Abpro Holdings ( ($ABP) ). On November 4, 2025, Abpro Holdings and...

2M ago

ABP

Abpro Holdings Announces Reverse Stock Split Effectiveness

Abpro Holdings ( ($ABP) ) just unveiled an update. On November 3, 2025, Abpro Holdings, Inc. announced the...

2M ago

ABP

Abpro Holdings announces 1-for-30 reverse stock split

Abpro announced that its previously approved 1-for-30 reverse stock split of its common stock became effective at 5:01...

2M ago

ABP

Upcoming Stock Splits This Week (November 3 to November 7) – Stay Invested

These are the upcoming stock splits for the week of November 3 to November 7, based on TipRanks’ Stock...

2M ago

ABP

RAY

ABPRO Holdings Inc trading halted, news pending

19:50 EDT ABPRO Holdings (ABP) Inc trading halted, news pending Published first on TheFly – the ultimate source...

3M ago

ABP

ABP FAQ

What was Abpro Holdings’s price range in the past 12 months?

Abpro Holdings lowest stock price was $3.78 and its highest was $42.90 in the past 12 months.

What is Abpro Holdings’s market cap?

Abpro Holdings’s market cap is $10.58M.

When is Abpro Holdings’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Abpro Holdings’s earnings last quarter?

Currently, no data Available

Is Abpro Holdings overvalued?

According to Wall Street analysts Abpro Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Abpro Holdings pay dividends?

Abpro Holdings does not currently pay dividends.

What is Abpro Holdings’s EPS estimate?

Abpro Holdings’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Abpro Holdings have?

Abpro Holdings has 2,716,278 shares outstanding.

What happened to Abpro Holdings’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Abpro Holdings?

Currently, no hedge funds are holding shares in ABP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Abpro Holdings

Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

ABP Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"$88","177":"$177","266":"$266","355":"$355","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,88,177,266,355],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.74,6.2215384615384615,5.703076923076923,5.184615384615385,4.666153846153846,4.147692307692307,3.629230769230769,3.1107692307692307,2.592307692307692,2.0738461538461532,1.5553846153846145,1.0369230769230766,0.5184615384615379,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.74,6.2215384615384615,5.703076923076923,5.184615384615385,4.666153846153846,4.147692307692307,3.629230769230769,3.1107692307692307,2.592307692307692,2.0738461538461532,1.5553846153846145,1.0369230769230766,0.5184615384615379,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.74,6.2215384615384615,5.703076923076923,5.184615384615385,4.666153846153846,4.147692307692307,3.629230769230769,3.1107692307692307,2.592307692307692,2.0738461538461532,1.5553846153846145,1.0369230769230766,0.5184615384615379,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":335.25,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":341.1,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":339.9,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":354,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":330,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":329.59,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":334.95,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":346.5,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":78.9,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":28.54,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":28.54,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >